Top papers for 2020 - Radiation Oncology

Read here the most important papers in Radiation Oncology this year.

Source: Top Papers for 2020 - Radiation Oncology (shared collection) [Internet]. Read.qxmd.com. 2020 [cited 29 December 2020]. Available from: https://read.qxmd.com/collection/22121?sid=adea2753-d897-4e24-bd70-dad41e492317.

Saudi Assembly for Radiation Oncology (SARO) proposals on outbreak of Corinavirus (COVID-19)

Recommendations of the Brazilian Radiotherapy Society on COVID-19

Recommendations of the SBRT (Sociedade Brasileira de Radioterapia [Brazilian Radiotherapy Society]) on COVID-19 (Coronavirus disease 2019):

[Portuguese]

Link to clarifications from the SBRT on the care to be taken with patients undergoing radiation therapy during the COVID-19 pandemic: http://sbradioterapia.com.br/noticias/radioterapia-e-ncovid-19-esclarecimentos-da-sbrt/ [Portuguese]. Accessed March 16, 2020.

EORTC-1333-GUCG PEACE III trial - Interview Prof. Bertrand Tombal

GUCG = Genito-Urinary Cancers Group; EORTC; PEACE = Prostate Cancer Consortium in Europe.

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease - European Journal of Cancer

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease - European Journal of Cancer: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non–small-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting.

Highlights:

• •The majority aimed to cure sOM NSCLC patients.
• •The maximum number of metastases considered in sOM-d was 42% ≤ 3 and 17% ≥ 5.
• •Most considered only ≤3 involved organs (excluding primary).
• •Few counted mediastinal lymph node as a metastatic site.
• •The preferred primary outcome for sOM clinical trials was overall survival.

Bibliographic reference: Levy A, Hendriks LEL, Berghmans T, et al. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. Eur J Cancer. 2019;122:109-114. Available at: https://doi.org/10.1016/j.ejca.2019.09.012.

What is the optimal timing for post-surgery radiotherapy?

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience: Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting.

2018 ASTRO: SABR-COMET: High-dose radiation therapy substantially improves survival in patients once thought to be incurable

ASTRO: American Society for Radiation Oncology; SABR-COMET: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors.

Heart radiation

Source: Kim M. Radiating The Heart Saves Patty Sweeney. ABC30 Fresno. https://abc30.com/health/radiating-the-heart-saves-patty-sweeney/3966266/. Published 2018. Accessed August 18, 2018.

Failed randomized clinical trials in Radiation Oncology: what can we learn?

Failed randomized clinical trials in Radiation Oncology: what can we learn?: Randomized clinical trials are essential to evidence-based medicine, yet a significant proportion fail to be completed. In Radiation Oncology, factors contributing to trial failure are not well understood. We sought to compare completed and incomplete clinical trials involving radiation therapy to identify predictors of trial failure.

Comparison of local recurrence among early breast cancer patients treated with electron intraoperative radiotherapy vs hypofractionated photon radiotherapy: an observational study

Comparison of local recurrence among early breast cancer patients treated with electron intraoperative radiotherapy vs hypofractionated photon radiotherapy: an observational study: PURPOSE: To evaluate local recurrence (LR) in women with early breast cancer (BC) who underwent intraoperative radiation therapy with electrons particles (IORT-E) or adjuvant hypofractionated external radiotherapy (HYPOFX). MATERIALS AND METHODS:We retrospectively analyzed 470 patients with early BC treated at our center from September 2009 to December 2012. 235 women were treated with breast-conserving surgery and immediate IORT-E (21 Gy/1 fraction) while 235 patients underwent wide excision followed by hypofractionated whole breast irradiation. Radiotherapy modality was chosen according an individualized decision based on tumour features, stage, technical feasibility, age, acceptance to be enrolled in the IORT-E group.RESULTS: After a median follow-up of 6 years, we observed 8 (3.4%) and 1 (0.42%) LR in the IORT-E and in the HYPOFX group (p=0.02), respectively. The two groups differed in the prevalence of clinical characteristics (p4 and 1 women in the IORT-E and HYPOFX group died for breast cancer, respectively (p=0.167). OS and DFS hazard ratio [HR] were 2.14 (95% IC, 1.10 to 4.15) and 2.09 (95% IC, 1.17 to 3.73), respectively. CONCLUSIONS:Our comparison showed that IORT-E and HYPOFX are two effective radiotherapy modalities after conservative surgery in early BC. However, at 6 years a significant higher rate of LR occurred in patients submitted to IORT-E with respect to HYPOFX. This finding may be correlated to some subsets of patients who, depending on the biological...

Radiotherapy utilization and fractionation patterns during the first course of cancer treatment in the United States from 2004 to 2014

Radiotherapy utilization and fractionation patterns during the first course of cancer treatment in the United States from 2004 to 2014: The changing use of radiation as a first-line cancer therapy in the United States is poorly characterized. This study aims to report radiotherapy utilization and fractionation patterns during the first course of cancer treatment.

Radiation beam to the heart

Source: Hallett M. Radiation beam to the heart - Outlook Magazine. Outlook Magazine. 2018. Available at: https://outlook.wustl.edu/radiation-beam-to-the-heart/. Accessed June 15, 2018.

The scarcity of funding for radiotherapy trials

Characteristics of radiotherapy trials compared With other oncological clinical trials in the past 10 years.

The limited number of and the scarcity of funding for radiotherapy trials is concerning given the integral role of radiotherapy in the clinical management of patients with cancer worldwide. A multidisciplinary collaboration to promote and fund more radiotherapy research is warranted.

Liu X, Zhang Y, Tang LL, et al. JAMA Oncol. 2018 May 17. Available at: https://doi.org/10.1001/jamaoncol.2018.0887.

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial: Journal of Clinical Oncology: Vol 36, No 13

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial: Journal of Clinical Oncology: Vol 36, No 13

Global Survey of Clinical Oncology Workforce: Journal of Global Oncology: Vol , No 4

Global Survey of Clinical Oncology Workforce: Journal of Global Oncology: Vol , No 4

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study: Most prostate cancer patients with a biochemical failure following primary multimodality treatment (surgery and postoperative radiotherapy) relapse in the nodes. Metastasis-directed therapy for these nodal recurrences might improve cancer-specific survival as compared with standard of care treatment.

Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer

Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer: To compare, using a cost-effectiveness analysis, the quality-adjusted life expectancy
(QALE) and cost between the 2 treatment options for intermediate- to high-risk prostate
cancer: (1) radiation (RT) with androgen deprivation therapy (ADT) or (2) radical
prostatectomy (RP) followed by adjuvant RT for patients with risk factors.

December 2017 issue of «highlights» from ENLIGHT

Highlights December 2017, from ENLIGHT.

Metastasis-directed treatment improves progression-free survival in prostate cancer

Check the Tweet @AmerUrological: https://twitter.com/AmerUrological/status/943111372270964736?s=09